The World Health Organization (WHO) advises that LAM should only be used on PLHIV with symptoms suggestive of pulmonary and/or extrapulmonary TB, with CD4 ≤100 cells/mm3 or in those seriously ill if CD4 cell counts are unavailable [10]. This evidence concerns the gene CD4 and tuberculosis.